Novartis to buy Avidity Biosciences for $12bn
PositiveFinancial Markets

Novartis has announced its acquisition of Avidity Biosciences for $12 billion, marking a significant move in the pharmaceutical industry. This deal, the largest under CEO Vas Narasimhan, highlights Novartis's commitment to expanding its portfolio in rare diseases, an area that has seen increasing demand for innovative treatments. The acquisition not only strengthens Novartis's position in the market but also promises to enhance patient care for those affected by rare conditions.
— Curated by the World Pulse Now AI Editorial System









